Form 8-K - Current report:
SEC Accession No. 0001819790-22-000002
Filing Date
2022-01-04
Accepted
2022-01-04 16:15:47
Documents
14
Period of Report
2021-12-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tars-20211231.htm   iXBRL 8-K 39575
2 EX-99.1 exhibit991tarsusappointsel.htm EX-99.1 13556
6 LOGO picture1a.jpg GRAPHIC 5866
  Complete submission text file 0001819790-22-000002.txt   207866

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20211231.xsd EX-101.SCH 1890
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20211231_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20211231_pre.xml EX-101.PRE 13035
8 EXTRACTED XBRL INSTANCE DOCUMENT tars-20211231_htm.xml XML 11334
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 22506090
SIC: 2836 Biological Products, (No Diagnostic Substances)